We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
18
5 active
Approvals
3
Total approvals
Agencies
1
Regulatory bodies
Founded
1925
Completed
9
50.0%
Not yet recruiting
5
27.8%
Recruiting
2
11.1%
Unknown
NMPA
National Medical Products Administration
- NJ Bio, Inc. and Ajinomoto Bio-Pharma Services announced a research collaboration to integrate the AJICAP™ site-specific conjugation platform into NJ Bio's discovery and development workflows for antibody-drug conjugates. - The AJICAP™ platform enables precise chemical modification at defined lysine residues without antibody engineering, preserving structure and functionality while improving pharmacokinetics and therapeutic index. - This partnership strengthens NJ Bio's position as a comprehensive partner for biopharmaceutical companies, offering end-to-end support from early drug design through preclinical development. - The collaboration is expected to reduce development risk, shorten timelines, and improve project outcomes for next-generation targeted therapeutics.